The therapeutic mechanism of action relies on drug binding to the extracellular domain IV of HER2, which triggers an intracellular cascade of tumor-suppressive actions including inhibition of oncogenic cellular signaling, and downregulation of angiogenesis and DNA repair pathways [89]. This evidence concerns the gene ERBB2 and neoplasm.